LinkedIn



HHS Guidelines Panels Issue Statement on Treating Latent Tuberculosis Infection in People Infected with HIV Receiving Antiretroviral Therapy

Posted December 2011

The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents and the HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children have issued a statement on treating latent tuberculosis infection in people infected with HIV who are receiving antiretroviral therapy.

Click here to see the statement: “Short-Course (3-Month) Therapy with Weekly Isoniazid-Rifapentine Is NOT RECOMMENDED for HIV-Infected Patients Receiving Antiretroviral Therapy.”

This communication is made in consultation with the HHS Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents and the HHS Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Children.